| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 86 | 2025 | 1000 | 8.050 |
Why?
|
| Troponin T | 48 | 2025 | 295 | 4.980 |
Why?
|
| Lipoprotein(a) | 17 | 2025 | 138 | 3.790 |
Why?
|
| Coronary Disease | 32 | 2024 | 679 | 3.300 |
Why?
|
| Cardiovascular Diseases | 47 | 2025 | 2062 | 3.260 |
Why?
|
| Natriuretic Peptide, Brain | 33 | 2024 | 339 | 2.840 |
Why?
|
| Biomarkers | 108 | 2025 | 3391 | 2.720 |
Why?
|
| Cholesterol, LDL | 21 | 2023 | 602 | 2.690 |
Why?
|
| Peptide Fragments | 32 | 2024 | 799 | 2.510 |
Why?
|
| C-Reactive Protein | 28 | 2025 | 466 | 2.430 |
Why?
|
| Lipoproteins | 11 | 2022 | 188 | 2.010 |
Why?
|
| Triglycerides | 16 | 2022 | 615 | 1.980 |
Why?
|
| Risk Factors | 121 | 2025 | 10912 | 1.900 |
Why?
|
| Heart Failure | 35 | 2025 | 2387 | 1.870 |
Why?
|
| Atrial Fibrillation | 18 | 2024 | 697 | 1.650 |
Why?
|
| Middle Aged | 180 | 2025 | 28895 | 1.650 |
Why?
|
| Prospective Studies | 76 | 2025 | 6540 | 1.520 |
Why?
|
| Diabetes Mellitus | 16 | 2022 | 922 | 1.520 |
Why?
|
| Risk Assessment | 52 | 2025 | 3710 | 1.480 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 13 | 2019 | 94 | 1.430 |
Why?
|
| Aged | 114 | 2025 | 21386 | 1.370 |
Why?
|
| Incidence | 65 | 2025 | 3362 | 1.360 |
Why?
|
| Stroke | 17 | 2023 | 1068 | 1.270 |
Why?
|
| Inflammation | 18 | 2024 | 1526 | 1.220 |
Why?
|
| Cholesterol | 11 | 2023 | 559 | 1.200 |
Why?
|
| Male | 193 | 2025 | 65072 | 1.150 |
Why?
|
| Female | 192 | 2025 | 70809 | 1.140 |
Why?
|
| Peripheral Arterial Disease | 7 | 2021 | 321 | 1.110 |
Why?
|
| Brain Ischemia | 6 | 2023 | 277 | 1.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 24 | 2024 | 1413 | 1.030 |
Why?
|
| Lipoproteins, LDL | 6 | 2021 | 137 | 1.020 |
Why?
|
| Humans | 230 | 2025 | 132373 | 1.000 |
Why?
|
| Troponin I | 8 | 2025 | 123 | 0.990 |
Why?
|
| Proteomics | 9 | 2025 | 594 | 0.990 |
Why?
|
| Lipids | 8 | 2021 | 563 | 0.960 |
Why?
|
| Lipoproteins, HDL | 6 | 2025 | 117 | 0.930 |
Why?
|
| Metabolic Syndrome | 11 | 2017 | 365 | 0.920 |
Why?
|
| Proportional Hazards Models | 28 | 2021 | 1451 | 0.870 |
Why?
|
| Coronary Artery Disease | 12 | 2024 | 892 | 0.840 |
Why?
|
| Hypertension | 10 | 2022 | 1343 | 0.840 |
Why?
|
| United States | 71 | 2025 | 11631 | 0.830 |
Why?
|
| Weight Loss | 10 | 2015 | 515 | 0.820 |
Why?
|
| Galectin 3 | 5 | 2022 | 37 | 0.790 |
Why?
|
| Cholesterol, HDL | 12 | 2021 | 395 | 0.780 |
Why?
|
| Apolipoproteins E | 4 | 2021 | 201 | 0.770 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2025 | 742 | 0.730 |
Why?
|
| Obesity | 16 | 2022 | 2406 | 0.730 |
Why?
|
| Cohort Studies | 41 | 2023 | 5153 | 0.700 |
Why?
|
| Chemokine CCL2 | 7 | 2021 | 119 | 0.690 |
Why?
|
| Prediabetic State | 2 | 2018 | 64 | 0.670 |
Why?
|
| Apolipoprotein C-III | 3 | 2022 | 46 | 0.660 |
Why?
|
| Blood Glucose | 16 | 2018 | 1171 | 0.660 |
Why?
|
| Lactic Acid | 7 | 2015 | 159 | 0.650 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 189 | 0.600 |
Why?
|
| Blood Pressure | 11 | 2024 | 1373 | 0.600 |
Why?
|
| Myocardial Infarction | 7 | 2024 | 1061 | 0.580 |
Why?
|
| Aged, 80 and over | 25 | 2025 | 7112 | 0.580 |
Why?
|
| Blood Proteins | 7 | 2025 | 137 | 0.570 |
Why?
|
| Prognosis | 29 | 2023 | 5010 | 0.560 |
Why?
|
| Deoxyglucose | 4 | 2020 | 43 | 0.540 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 2012 | 123 | 0.520 |
Why?
|
| Inflammation Mediators | 5 | 2020 | 242 | 0.510 |
Why?
|
| Apolipoproteins B | 6 | 2019 | 146 | 0.510 |
Why?
|
| Follow-Up Studies | 30 | 2021 | 5405 | 0.510 |
Why?
|
| Alzheimer Disease | 5 | 2025 | 865 | 0.500 |
Why?
|
| Albuminuria | 7 | 2022 | 113 | 0.490 |
Why?
|
| Dehydroepiandrosterone Sulfate | 3 | 2020 | 24 | 0.490 |
Why?
|
| Predictive Value of Tests | 19 | 2024 | 2303 | 0.480 |
Why?
|
| Cyclic GMP | 3 | 2021 | 95 | 0.480 |
Why?
|
| Carotid Artery Diseases | 3 | 2014 | 138 | 0.480 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 61 | 0.470 |
Why?
|
| Calcinosis | 4 | 2024 | 191 | 0.460 |
Why?
|
| Time Factors | 24 | 2024 | 6457 | 0.450 |
Why?
|
| Polymorphism, Single Nucleotide | 14 | 2017 | 2851 | 0.430 |
Why?
|
| Adiponectin | 9 | 2023 | 128 | 0.430 |
Why?
|
| Alanine Transaminase | 4 | 2023 | 160 | 0.430 |
Why?
|
| Menopause | 2 | 2022 | 90 | 0.420 |
Why?
|
| Cross-Sectional Studies | 23 | 2023 | 3745 | 0.410 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2013 | 50 | 0.410 |
Why?
|
| Receptors, Immunologic | 4 | 2014 | 127 | 0.400 |
Why?
|
| Hospitalization | 12 | 2021 | 1895 | 0.400 |
Why?
|
| Residence Characteristics | 8 | 2017 | 284 | 0.400 |
Why?
|
| Hydroxycholesterols | 1 | 2012 | 4 | 0.390 |
Why?
|
| Aspartate Aminotransferases | 3 | 2021 | 83 | 0.390 |
Why?
|
| Case-Control Studies | 19 | 2020 | 3422 | 0.390 |
Why?
|
| Vascular Calcification | 2 | 2024 | 68 | 0.380 |
Why?
|
| Genome-Wide Association Study | 15 | 2021 | 1831 | 0.380 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2024 | 422 | 0.370 |
Why?
|
| Receptor for Advanced Glycation End Products | 6 | 2018 | 31 | 0.370 |
Why?
|
| Heart Diseases | 4 | 2020 | 511 | 0.360 |
Why?
|
| Cystatin C | 6 | 2016 | 65 | 0.350 |
Why?
|
| Life Style | 5 | 2018 | 455 | 0.350 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 803 | 0.350 |
Why?
|
| Diabetes Complications | 3 | 2020 | 205 | 0.350 |
Why?
|
| Phospholipases A | 3 | 2005 | 36 | 0.340 |
Why?
|
| Models, Biological | 3 | 2014 | 1458 | 0.340 |
Why?
|
| Population Surveillance | 2 | 2021 | 416 | 0.330 |
Why?
|
| Spouse Abuse | 1 | 2010 | 16 | 0.330 |
Why?
|
| Apolipoproteins | 3 | 2012 | 72 | 0.330 |
Why?
|
| Growth Differentiation Factor 15 | 4 | 2023 | 28 | 0.330 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2010 | 165 | 0.330 |
Why?
|
| Carotid Arteries | 2 | 2010 | 136 | 0.330 |
Why?
|
| Venous Thromboembolism | 3 | 2018 | 186 | 0.320 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 63 | 0.320 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2020 | 50 | 0.320 |
Why?
|
| Models, Psychological | 1 | 2010 | 144 | 0.310 |
Why?
|
| Brain | 7 | 2025 | 3200 | 0.310 |
Why?
|
| Risk | 12 | 2018 | 763 | 0.310 |
Why?
|
| Glomerular Filtration Rate | 10 | 2022 | 536 | 0.300 |
Why?
|
| Galectins | 4 | 2022 | 26 | 0.290 |
Why?
|
| Alcohol Drinking | 5 | 2023 | 359 | 0.280 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2021 | 623 | 0.280 |
Why?
|
| Ventricular Remodeling | 3 | 2024 | 168 | 0.260 |
Why?
|
| Monocytes | 3 | 2019 | 345 | 0.260 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 244 | 0.260 |
Why?
|
| Genetic Loci | 6 | 2017 | 362 | 0.260 |
Why?
|
| Body Mass Index | 13 | 2024 | 1707 | 0.260 |
Why?
|
| Comorbidity | 6 | 2024 | 1605 | 0.260 |
Why?
|
| Testosterone | 3 | 2020 | 611 | 0.260 |
Why?
|
| Sensitivity and Specificity | 12 | 2021 | 2145 | 0.260 |
Why?
|
| Fructosamine | 3 | 2018 | 12 | 0.250 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 545 | 0.250 |
Why?
|
| gamma-Glutamyltransferase | 3 | 2014 | 47 | 0.250 |
Why?
|
| Apolipoprotein A-I | 3 | 2017 | 89 | 0.250 |
Why?
|
| Ischemia | 2 | 2020 | 373 | 0.240 |
Why?
|
| Ceruloplasmin | 2 | 2017 | 15 | 0.240 |
Why?
|
| Postprandial Period | 2 | 2016 | 91 | 0.240 |
Why?
|
| Disease Progression | 6 | 2024 | 2228 | 0.240 |
Why?
|
| Dyslipidemias | 2 | 2021 | 242 | 0.230 |
Why?
|
| Sex Factors | 10 | 2024 | 1350 | 0.230 |
Why?
|
| White Matter | 2 | 2018 | 211 | 0.230 |
Why?
|
| Vascular Stiffness | 3 | 2021 | 80 | 0.230 |
Why?
|
| Prevalence | 9 | 2020 | 2665 | 0.230 |
Why?
|
| Cardiomyopathies | 4 | 2019 | 508 | 0.230 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2023 | 91 | 0.230 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 80 | 0.220 |
Why?
|
| Varicose Veins | 1 | 2024 | 29 | 0.220 |
Why?
|
| Asymptomatic Diseases | 3 | 2020 | 87 | 0.220 |
Why?
|
| beta 2-Microglobulin | 3 | 2014 | 34 | 0.220 |
Why?
|
| Smoking | 9 | 2018 | 942 | 0.220 |
Why?
|
| Adult | 26 | 2023 | 31624 | 0.220 |
Why?
|
| Lipocalins | 3 | 2014 | 29 | 0.220 |
Why?
|
| Intramolecular Oxidoreductases | 3 | 2014 | 41 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2021 | 3853 | 0.220 |
Why?
|
| von Willebrand Factor | 2 | 2023 | 194 | 0.210 |
Why?
|
| Linear Models | 7 | 2017 | 713 | 0.210 |
Why?
|
| Cognition | 2 | 2019 | 814 | 0.210 |
Why?
|
| Dioxygenases | 1 | 2024 | 65 | 0.210 |
Why?
|
| Up-Regulation | 7 | 2020 | 879 | 0.200 |
Why?
|
| Kidney Diseases | 2 | 2021 | 488 | 0.200 |
Why?
|
| Hyperglycemia | 2 | 2018 | 238 | 0.200 |
Why?
|
| Blood Specimen Collection | 2 | 2015 | 47 | 0.200 |
Why?
|
| Sirolimus | 2 | 2002 | 241 | 0.200 |
Why?
|
| Women's Health | 2 | 2017 | 148 | 0.200 |
Why?
|
| Kidney | 5 | 2022 | 1331 | 0.200 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2017 | 153 | 0.200 |
Why?
|
| von Willebrand Diseases | 1 | 2023 | 54 | 0.200 |
Why?
|
| Kidney Failure, Chronic | 4 | 2014 | 903 | 0.200 |
Why?
|
| Proteome | 2 | 2021 | 278 | 0.200 |
Why?
|
| Cognition Disorders | 2 | 2019 | 571 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2016 | 830 | 0.190 |
Why?
|
| Creatinine | 5 | 2022 | 400 | 0.190 |
Why?
|
| Dementia | 2 | 2021 | 475 | 0.190 |
Why?
|
| Extracellular Matrix | 3 | 2019 | 238 | 0.190 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 13 | 0.190 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 155 | 0.190 |
Why?
|
| Phospholipases A2 | 4 | 2011 | 36 | 0.180 |
Why?
|
| Coronary Vessels | 2 | 2024 | 548 | 0.180 |
Why?
|
| Diabetic Angiopathies | 3 | 2020 | 72 | 0.180 |
Why?
|
| Protein Precursors | 3 | 2021 | 156 | 0.180 |
Why?
|
| Arteriosclerosis | 3 | 2007 | 122 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2002 | 672 | 0.170 |
Why?
|
| Interleukin-6 | 5 | 2024 | 438 | 0.170 |
Why?
|
| Genotype | 8 | 2017 | 2706 | 0.170 |
Why?
|
| Stroke Volume | 4 | 2025 | 534 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2022 | 178 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 615 | 0.170 |
Why?
|
| Aortic Valve | 1 | 2024 | 485 | 0.170 |
Why?
|
| Lipid Metabolism | 3 | 2019 | 389 | 0.170 |
Why?
|
| Postmenopause | 5 | 2020 | 153 | 0.160 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 108 | 0.160 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 9 | 0.160 |
Why?
|
| Myocardium | 3 | 2014 | 908 | 0.160 |
Why?
|
| Intermittent Claudication | 1 | 2020 | 59 | 0.160 |
Why?
|
| Medical History Taking | 1 | 2020 | 114 | 0.160 |
Why?
|
| Serum Albumin | 2 | 2018 | 114 | 0.160 |
Why?
|
| Diet, Western | 1 | 2019 | 18 | 0.160 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 32 | 0.160 |
Why?
|
| Aortic Valve Stenosis | 1 | 2024 | 378 | 0.160 |
Why?
|
| Repressor Proteins | 1 | 2024 | 815 | 0.150 |
Why?
|
| Heart Ventricles | 2 | 2021 | 781 | 0.150 |
Why?
|
| Oxidative Stress | 3 | 2022 | 800 | 0.150 |
Why?
|
| Kidney Transplantation | 2 | 2002 | 569 | 0.150 |
Why?
|
| Age Factors | 8 | 2020 | 2930 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2010 | 40 | 0.150 |
Why?
|
| Immunoassay | 5 | 2023 | 135 | 0.150 |
Why?
|
| Longitudinal Studies | 7 | 2020 | 1502 | 0.150 |
Why?
|
| Fibrosis | 3 | 2022 | 428 | 0.150 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 3024 | 0.150 |
Why?
|
| Interleukin-18 | 2 | 2023 | 68 | 0.140 |
Why?
|
| Aging | 3 | 2023 | 1261 | 0.140 |
Why?
|
| Insulin | 6 | 2014 | 1211 | 0.140 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Blood Chemical Analysis | 2 | 2015 | 86 | 0.140 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2017 | 8 | 0.140 |
Why?
|
| Adipokines | 1 | 2018 | 72 | 0.140 |
Why?
|
| Platelet Activation | 1 | 2017 | 70 | 0.140 |
Why?
|
| Leptin | 5 | 2018 | 219 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 365 | 0.130 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2014 | 97 | 0.130 |
Why?
|
| Logistic Models | 4 | 2016 | 1840 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 2 | 2015 | 272 | 0.130 |
Why?
|
| Cancer Survivors | 1 | 2019 | 251 | 0.120 |
Why?
|
| Cardiology | 1 | 2021 | 497 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2018 | 188 | 0.120 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 3088 | 0.120 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2016 | 22 | 0.120 |
Why?
|
| Lysine | 2 | 2015 | 201 | 0.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 198 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2020 | 517 | 0.120 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 29 | 0.120 |
Why?
|
| Phenotype | 5 | 2024 | 4545 | 0.120 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2016 | 110 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2021 | 3358 | 0.120 |
Why?
|
| Caloric Restriction | 2 | 2013 | 97 | 0.120 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 1997 | 0.120 |
Why?
|
| Protein Phosphatase 1 | 1 | 2015 | 54 | 0.120 |
Why?
|
| Diabetic Foot | 1 | 2018 | 167 | 0.120 |
Why?
|
| Acute Kidney Injury | 2 | 2021 | 667 | 0.120 |
Why?
|
| Alleles | 3 | 2015 | 1683 | 0.120 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 26 | 0.120 |
Why?
|
| Fatty Acids, Nonesterified | 3 | 2006 | 138 | 0.110 |
Why?
|
| Liver | 4 | 2021 | 1816 | 0.110 |
Why?
|
| Hypoglycemia | 1 | 2016 | 189 | 0.110 |
Why?
|
| Overweight | 2 | 2015 | 384 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 313 | 0.110 |
Why?
|
| Glycation End Products, Advanced | 4 | 2018 | 28 | 0.110 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 33 | 0.110 |
Why?
|
| Metformin | 2 | 2015 | 165 | 0.110 |
Why?
|
| Social Class | 1 | 2016 | 207 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 1126 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 281 | 0.110 |
Why?
|
| Subtilisins | 1 | 2014 | 13 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 147 | 0.110 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2013 | 42 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 1683 | 0.110 |
Why?
|
| Echocardiography | 3 | 2024 | 1125 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 373 | 0.110 |
Why?
|
| Athletes | 1 | 2014 | 73 | 0.100 |
Why?
|
| Particle Size | 1 | 2014 | 149 | 0.100 |
Why?
|
| Exome | 1 | 2018 | 1086 | 0.100 |
Why?
|
| Brain Infarction | 1 | 2013 | 30 | 0.100 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2013 | 29 | 0.100 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2018 | 425 | 0.100 |
Why?
|
| Odds Ratio | 6 | 2014 | 1256 | 0.100 |
Why?
|
| Global Health | 1 | 2018 | 620 | 0.100 |
Why?
|
| Apolipoprotein B-100 | 3 | 2001 | 39 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1313 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2004 | 295 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 61 | 0.100 |
Why?
|
| Genetic Variation | 3 | 2017 | 1583 | 0.100 |
Why?
|
| Adipose Tissue | 3 | 2011 | 513 | 0.100 |
Why?
|
| Body Weight | 2 | 2014 | 1006 | 0.100 |
Why?
|
| Hypoglycemic Agents | 2 | 2015 | 482 | 0.100 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2012 | 11 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 137 | 0.100 |
Why?
|
| General Practice | 1 | 2012 | 8 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 530 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2012 | 81 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2015 | 352 | 0.090 |
Why?
|
| Amyloid beta-Peptides | 2 | 2024 | 234 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2013 | 220 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 728 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2012 | 127 | 0.090 |
Why?
|
| Organ Size | 2 | 2025 | 447 | 0.090 |
Why?
|
| Fasting | 3 | 2014 | 308 | 0.090 |
Why?
|
| Apolipoproteins A | 2 | 2001 | 54 | 0.090 |
Why?
|
| Survival Rate | 4 | 2018 | 2187 | 0.090 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 232 | 0.090 |
Why?
|
| tau Proteins | 2 | 2024 | 237 | 0.090 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 100 | 0.090 |
Why?
|
| Independent Living | 2 | 2024 | 72 | 0.080 |
Why?
|
| Zinc | 1 | 2011 | 140 | 0.080 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 7 | 0.080 |
Why?
|
| Vasculitis | 1 | 2011 | 50 | 0.080 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 52 | 0.080 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 39 | 0.080 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 58 | 0.080 |
Why?
|
| Dehydroepiandrosterone | 1 | 2010 | 33 | 0.080 |
Why?
|
| Temperature | 1 | 2011 | 304 | 0.080 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 66 | 0.080 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 68 | 0.080 |
Why?
|
| Prolactin | 1 | 2010 | 113 | 0.080 |
Why?
|
| Pulse Wave Analysis | 2 | 2021 | 51 | 0.080 |
Why?
|
| Duffy Blood-Group System | 1 | 2009 | 9 | 0.080 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2010 | 23 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2010 | 66 | 0.080 |
Why?
|
| P-Selectin | 1 | 2010 | 68 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2021 | 1443 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2010 | 235 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2010 | 123 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 440 | 0.080 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 105 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 741 | 0.080 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2009 | 76 | 0.070 |
Why?
|
| Mortality | 2 | 2020 | 257 | 0.070 |
Why?
|
| Blood Platelets | 2 | 2010 | 325 | 0.070 |
Why?
|
| Proteins | 2 | 2004 | 1064 | 0.070 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 585 | 0.070 |
Why?
|
| Angiopoietins | 1 | 2008 | 21 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1009 | 0.070 |
Why?
|
| Estrone | 1 | 2008 | 12 | 0.070 |
Why?
|
| Glycoproteins | 2 | 2024 | 377 | 0.070 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 23 | 0.070 |
Why?
|
| Electrocardiography | 3 | 2017 | 990 | 0.070 |
Why?
|
| Coronary Angiography | 2 | 2024 | 484 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 452 | 0.070 |
Why?
|
| Statistics as Topic | 2 | 2014 | 254 | 0.070 |
Why?
|
| Cause of Death | 2 | 2020 | 503 | 0.070 |
Why?
|
| Primary Prevention | 2 | 2020 | 178 | 0.070 |
Why?
|
| Iron Overload | 1 | 2007 | 16 | 0.070 |
Why?
|
| Health Promotion | 1 | 2010 | 404 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 804 | 0.060 |
Why?
|
| Cytokines | 2 | 2010 | 1368 | 0.060 |
Why?
|
| Ferritins | 1 | 2007 | 108 | 0.060 |
Why?
|
| Community-Based Participatory Research | 2 | 2018 | 56 | 0.060 |
Why?
|
| Young Adult | 5 | 2022 | 9949 | 0.060 |
Why?
|
| HIV Infections | 2 | 2015 | 2063 | 0.060 |
Why?
|
| Rosuvastatin Calcium | 2 | 2017 | 43 | 0.060 |
Why?
|
| Fibrinogen | 2 | 2017 | 157 | 0.060 |
Why?
|
| Estradiol | 1 | 2008 | 488 | 0.060 |
Why?
|
| Factor VIII | 2 | 2017 | 48 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2024 | 1049 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 1247 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2024 | 1229 | 0.060 |
Why?
|
| Critical Illness | 2 | 2020 | 617 | 0.060 |
Why?
|
| Nutrition Surveys | 2 | 2020 | 314 | 0.060 |
Why?
|
| Walking Speed | 1 | 2024 | 18 | 0.050 |
Why?
|
| Mobility Limitation | 1 | 2024 | 33 | 0.050 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2024 | 14 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 235 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2001 | 304 | 0.050 |
Why?
|
| Caveolins | 1 | 2003 | 16 | 0.050 |
Why?
|
| Colchicine | 1 | 2023 | 38 | 0.050 |
Why?
|
| United Kingdom | 1 | 2024 | 234 | 0.050 |
Why?
|
| Calcium | 2 | 2022 | 1083 | 0.050 |
Why?
|
| Azetidines | 2 | 2013 | 64 | 0.050 |
Why?
|
| Simvastatin | 2 | 2013 | 77 | 0.050 |
Why?
|
| Ezetimibe | 2 | 2013 | 94 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2024 | 155 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2023 | 67 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 651 | 0.050 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 215 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 158 | 0.050 |
Why?
|
| ROC Curve | 2 | 2018 | 598 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 901 | 0.050 |
Why?
|
| Proteinuria | 1 | 2022 | 108 | 0.050 |
Why?
|
| Waist Circumference | 2 | 2014 | 95 | 0.050 |
Why?
|
| Kidney Function Tests | 2 | 2013 | 131 | 0.050 |
Why?
|
| Anoctamins | 1 | 2021 | 14 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2019 | 17371 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 856 | 0.050 |
Why?
|
| Lipoproteins, VLDL | 1 | 2001 | 57 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1649 | 0.050 |
Why?
|
| Energy Intake | 1 | 2004 | 519 | 0.040 |
Why?
|
| Neutrophils | 1 | 2023 | 359 | 0.040 |
Why?
|
| Mutation | 1 | 2015 | 6250 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 237 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2021 | 169 | 0.040 |
Why?
|
| India | 1 | 2001 | 240 | 0.040 |
Why?
|
| Mass Screening | 2 | 2018 | 831 | 0.040 |
Why?
|
| Calibration | 2 | 2015 | 99 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2001 | 188 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 422 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2013 | 13020 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 801 | 0.040 |
Why?
|
| Educational Status | 2 | 2016 | 295 | 0.040 |
Why?
|
| Erythrocytes | 2 | 2011 | 222 | 0.040 |
Why?
|
| Obesity, Morbid | 1 | 2022 | 212 | 0.040 |
Why?
|
| Diastole | 1 | 2020 | 179 | 0.040 |
Why?
|
| Exercise | 2 | 2017 | 865 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 179 | 0.040 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 48 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 201 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 191 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 5 | 0.040 |
Why?
|
| Reference Values | 2 | 2014 | 721 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 275 | 0.040 |
Why?
|
| American Heart Association | 1 | 2020 | 309 | 0.030 |
Why?
|
| Memory, Episodic | 1 | 2017 | 28 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 45 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2000 | 615 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2018 | 117 | 0.030 |
Why?
|
| England | 1 | 2017 | 63 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 156 | 0.030 |
Why?
|
| Leg | 1 | 2018 | 134 | 0.030 |
Why?
|
| Vitamin E | 1 | 2017 | 65 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 249 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2018 | 324 | 0.030 |
Why?
|
| Equipment Design | 1 | 2019 | 605 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 433 | 0.030 |
Why?
|
| RNA Editing | 1 | 1996 | 36 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.030 |
Why?
|
| Insulin Resistance | 2 | 2012 | 703 | 0.030 |
Why?
|
| Maryland | 1 | 2016 | 34 | 0.030 |
Why?
|
| Mississippi | 1 | 2016 | 35 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 80 | 0.030 |
Why?
|
| North Carolina | 1 | 2016 | 66 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2016 | 51 | 0.030 |
Why?
|
| Copper | 1 | 1996 | 75 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 911 | 0.030 |
Why?
|
| Diet, Reducing | 2 | 2008 | 94 | 0.030 |
Why?
|
| Aspirin | 1 | 2017 | 221 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 253 | 0.030 |
Why?
|
| Minnesota | 1 | 2016 | 179 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 46 | 0.030 |
Why?
|
| Troponin | 1 | 2016 | 79 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1570 | 0.030 |
Why?
|
| Selection Bias | 1 | 2015 | 19 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 778 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 989 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 288 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2018 | 375 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2015 | 93 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 125 | 0.030 |
Why?
|
| Retirement | 1 | 2014 | 18 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 409 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 39 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1577 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2006 | 276 | 0.030 |
Why?
|
| Football | 1 | 2014 | 36 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 256 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 2169 | 0.030 |
Why?
|
| Absorption | 1 | 2013 | 52 | 0.030 |
Why?
|
| Sitosterols | 1 | 2013 | 10 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 198 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 94 | 0.030 |
Why?
|
| Diet | 2 | 2013 | 1174 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 110 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 206 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 39 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 806 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 59 | 0.030 |
Why?
|
| Hyperlipoproteinemia Type IV | 1 | 2013 | 3 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 373 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 111 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1996 | 1098 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 171 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2015 | 184 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2013 | 94 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 165 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2015 | 392 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2013 | 94 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2013 | 168 | 0.020 |
Why?
|
| Cholesterol Esters | 1 | 2012 | 16 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 311 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 239 | 0.020 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 60 | 0.020 |
Why?
|
| Complement C3 | 1 | 2012 | 51 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2017 | 988 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 142 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 667 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 751 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 748 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2012 | 148 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1046 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2012 | 173 | 0.020 |
Why?
|
| Zinc Transporter 8 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 282 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 319 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 49 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1454 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 40 | 0.020 |
Why?
|
| CD11c Antigen | 1 | 2011 | 40 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 956 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 210 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 490 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2010 | 59 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 18572 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 419 | 0.020 |
Why?
|
| Protein Binding | 2 | 2006 | 1735 | 0.020 |
Why?
|
| Animals | 5 | 2019 | 34996 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 3062 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 103 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2010 | 124 | 0.020 |
Why?
|
| Glycolysis | 1 | 2010 | 167 | 0.020 |
Why?
|
| Diet, High-Fat | 1 | 2011 | 255 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 212 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2009 | 150 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4695 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 818 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 100 | 0.020 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2008 | 85 | 0.020 |
Why?
|
| Premenopause | 1 | 2008 | 40 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 508 | 0.020 |
Why?
|
| Nutritional Sciences | 1 | 2008 | 76 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 1098 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 1829 | 0.020 |
Why?
|
| Community Health Services | 1 | 2008 | 93 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 278 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4725 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2006 | 25 | 0.020 |
Why?
|
| Static Electricity | 1 | 2006 | 47 | 0.020 |
Why?
|
| Adolescent | 2 | 2015 | 20560 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 4767 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 459 | 0.010 |
Why?
|
| Microspheres | 1 | 2005 | 74 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 212 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 265 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2003 | 50 | 0.010 |
Why?
|
| Sports | 1 | 2004 | 66 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 117 | 0.010 |
Why?
|
| Body Height | 1 | 2004 | 227 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 688 | 0.010 |
Why?
|
| Neoplasms | 1 | 2017 | 2949 | 0.010 |
Why?
|
| Aminocaproic Acid | 1 | 2001 | 4 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 2001 | 21 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 368 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2001 | 83 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 2904 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2001 | 33 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2001 | 147 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 310 | 0.010 |
Why?
|
| Proline | 1 | 2001 | 76 | 0.010 |
Why?
|
| Tranexamic Acid | 1 | 2001 | 33 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 1085 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3780 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2001 | 114 | 0.010 |
Why?
|
| Radiology, Interventional | 1 | 2000 | 35 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 2000 | 124 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 1357 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2000 | 147 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1672 | 0.010 |
Why?
|
| Models, Cardiovascular | 1 | 2000 | 183 | 0.010 |
Why?
|
| Arginine | 1 | 2001 | 342 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 3629 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2000 | 443 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2730 | 0.010 |
Why?
|
| Apolipoprotein B-48 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1996 | 29 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 381 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1996 | 383 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 454 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 576 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 813 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 1227 | 0.010 |
Why?
|
| Gene Expression | 1 | 1996 | 1564 | 0.010 |
Why?
|
| Rats | 1 | 1996 | 3620 | 0.010 |
Why?
|